Beverly Wolfer’s professional career spans the corporate and not-for-profit sectors. Beverly worked in banking at Riggs National Bank and management consulting with Booz Allen & Hamilton. She sits on the Board of The Jewish Welfare Board, JCCA and is the President of a family foundation dedicated to supporting our Troops. Beverly received her B.B.A. from The George Washington University and her M.B.A. from The Darden School, University of Virginia.
Joyce Liu, MD, MPH, joined the staff of Dana-Farber and Brigham and Women’s Hospital in 2008, where she is a medical oncologist and clinical investigator in the Gynecologic Oncology Program. She received her MD from Harvard Medical School and completed her residency in Internal Medicine at Brigham and Women’s Hospital, and her fellowship in Hematology Oncology at the Dana-Farber Cancer Institute. Dr. Liu’s research focuses on identifying and validating potential therapeutic targets in advanced platinum-resistant ovarian cancer, in an in-vitro setting as well as in a mouse model of ovarian cancer.
Dr. Liu was awarded The Columbia Hospital Research Foundation Annual Award for Research Excellence in Breast, Obstetrical and Gynecologic Disorders.
In the 5th issue of Dana-Farber’s Inside the Institute, Dr. Liu discusses the importance of federal funding after her successful clinical trial, which was funded by the National Cancer Institute, proved that a novel two-drug combination nearly doubled progression-free survival for many women with ovarian cancer.
Charles “Chip” Landen, MD is a gynecologic oncologist and an Associate Professor in the Gynecologic Oncology Division at the University of Virginia and the Associate Leader of the Women’s Oncology Program at the UVA Cancer Center.
Dr. Landen received his MD from the University of North Carolina School of Medicine. He completed his residency at the Medical University of South Carolina and his fellowship in gynecologic oncology at the University of Texas MD Anderson Cancer Center.
As a Tina’s Wish 2017/18 funded researcher, Dr. Landen has shown that DNA from ovarian cancer cells within the peritoneal cavity (the area that contains the abdominal organs) can be detected in the discharge collected on a tampon specimen after being placed overnight in patients with advanced ovarian cancer. Dr. Landen’s lab is performing experiments to see if this noninvasive method can be used for detection of early-stage, or even premalignant, ovarian cancer.
Project Title: “Integration of Advanced Genomic and Bioengineering Approaches for Early Detection and Prevention of Ovarian Cancer”
Tina’s Wish is honored to present its second Consortium Grant to this cutting edge team of researchers who will collaborate together for the next three years.
Project Title: “Deciphering the mechanisms and relevance of replication stress in ovarian cancer precursor cells”
Dr. Hill is a gynecologic pathologist and an independent investigator at Dana-Farber Cancer Institute.
